StockData
Enliven Therapeutics, Inc. logo

Enliven Therapeutics, Inc. (ELVN) stock

ELVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$44.89−1.96 (-4.18%)

Close on Nov 18, 2026Market cap $3.29BP/E –Yield –

Enliven Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Enliven Therapeutics's price to book ratio was 4.2× on Nov 11, 2026, against 2.7× a year earlier. Over the last 5 years it ranged from 0.2× to 7.4×, with a median of 2.8×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20264.2×+2.3
2025Dec 31, 20251.9×−1.8
2024Dec 31, 20243.7×+1.5
2023Dec 29, 20232.2×+2.0
2022Jan 31, 20220.2×−0.1
2021Dec 31, 20210.3×−1.7
2020Dec 31, 20201.9×–

More Enliven Therapeutics figures

See a number that looks wrong?